[{"arm_notes": "", "treatment_id": null, "treatment_name": "After referral to the the non-ICU COVID-19 ward; the patients were treated with dexamethasone standard therapy. After being randomized by sealed envelope the patients receive convalescent plasma or placebo treatment added to the standard therapy. An interim-analysis for efficacy and harm will be performed on the primary endpoint when 50% of patients have been included and have been followed up for at least 30 days; and follow-up will continue until discharge or death before day 60.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 322, "treatment_name": "Convalescent plasma", "treatment_type": "Convalescent plasma", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]